Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) has announced the results of the voting conducted during its Annual General Meeting (AGM), which took place on May 23, 2024, in Marseille. Shareholders voted on all proposed resolutions, demonstrating active participation in the governance of the company.
A total of 84 votes were cast, representing 36,798,714 voting rights out of the total 36,317,268 shares issued by the company. This participation rate accounts for a quorum of 44.92%.
During the AGM, shareholders re-elected two members of the Supervisory Board, ensuring continuity in the company’s strategic oversight. The detailed outcomes of all resolutions, along with additional documents and the recording of the AGM, will be made accessible on Innate Pharma’s website under the Annual General Meeting 2024 section.
About Innate Pharma
Innate Pharma S.A. is a globally recognized clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company’s unique approach aims to harness the innate immune system through the development of therapeutic antibodies and its proprietary ANKET® platform.
Innate’s robust portfolio includes several key programs:
- Lacutamab: A lead proprietary program designed to treat advanced forms of cutaneous T cell lymphomas and peripheral T cell lymphomas.
- Monalizumab: Developed in collaboration with AstraZeneca, this program targets non-small cell lung cancer.
- ANKET® Multi-Specific NK Cell Engagers: These are designed to address multiple tumor types, reflecting the versatility and potential of the ANKET® platform.
Innate Pharma’s strategic partnerships with prominent biopharmaceutical companies like Sanofi and AstraZeneca, as well as with leading research institutions, are crucial in accelerating innovation and advancing research and development efforts. These collaborations aim to bring cutting-edge therapies to patients more efficiently.
Headquartered in Marseille, France, and with an office in Rockville, Maryland, USA, Innate Pharma maintains a strong presence in both European and American markets. The company’s stocks are publicly traded on Euronext Paris and Nasdaq in the United States, underlining its significant role in the global biotechnology landscape.
